...
search icon
inva-img

Innoviva Inc, Common Stock

INVA

NSQ

$18.32

-$0.09

(-0.49%)

1D
Industry: Pharmaceuticals Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$1.15B
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
23.0125
Volume info-icon
This is the total number of shares traded during the most recent trading day.
634.97K
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
0.57
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$14.33 L
$21.28 H
$18.32

About Innoviva Inc, Common Stock

Innoviva, Inc. engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company's products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; GIAPREZA (angiotensin II), a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock; XERAVA (eravacycline) for the treatment of complicated intra-abdominal infections in adults; and XACDURO, a beta lactamase inhibitor for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. Its development pipeline includes zoliflodacin, a late-stage product candidate, a potential single oral dose cure for the treatment of uncomplicated gonorrhea. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. It has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California. more

Industry: PharmaceuticalsSector: Health Care

Returns

Time FrameINVASectorS&P500
1-Week Return-2.5%0.63%-1.11%
1-Month Return5.41%6.06%0.39%
3-Month Return-5.37%0.46%4.94%
6-Month Return0.05%0.42%15.68%
1-Year Return15.8%3.52%21.45%
3-Year Return17.14%11.44%33.25%
5-Year Return29.47%44.83%81.76%
10-Year Return52.41%112.91%193.72%

Financials

Dec '19Dec '20Dec '21Dec '22Dec '235YR TREND
Total Revenue261.02M336.79M391.87M331.34M310.46M[{"date":"2019-12-31","value":66.61,"profit":true},{"date":"2020-12-31","value":85.95,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":84.55,"profit":true},{"date":"2023-12-31","value":79.23,"profit":true}]
Cost of Revenue-1.79M13.83M13.79M49.40M[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":3.62,"profit":true},{"date":"2021-12-31","value":28,"profit":true},{"date":"2022-12-31","value":27.92,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Gross Profit261.02M336.79K391.87M317.55M261.06M[{"date":"2019-12-31","value":66.61,"profit":true},{"date":"2020-12-31","value":0.09,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":81.03,"profit":true},{"date":"2023-12-31","value":66.62,"profit":true}]
Gross Margin100.00%0.10%100.00%95.84%84.09%[{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":0.1,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":95.84,"profit":true},{"date":"2023-12-31","value":84.09,"profit":true}]
Operating Expenses14.66M15.67M16.76M110.55M132.15M[{"date":"2019-12-31","value":11.09,"profit":true},{"date":"2020-12-31","value":11.86,"profit":true},{"date":"2021-12-31","value":12.68,"profit":true},{"date":"2022-12-31","value":83.65,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Operating Income246.36M321.12M375.10M209.99M176.71M[{"date":"2019-12-31","value":65.68,"profit":true},{"date":"2020-12-31","value":85.61,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":55.98,"profit":true},{"date":"2023-12-31","value":47.11,"profit":true}]
Total Non-Operating Income/Expense(26.59M)16.32M52.94M67.54M14.38M[{"date":"2019-12-31","value":-39.36,"profit":false},{"date":"2020-12-31","value":24.16,"profit":true},{"date":"2021-12-31","value":78.39,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":21.29,"profit":true}]
Pre-Tax Income232.90M354.25M445.28M286.95M194.10M[{"date":"2019-12-31","value":52.3,"profit":true},{"date":"2020-12-31","value":79.56,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":64.44,"profit":true},{"date":"2023-12-31","value":43.59,"profit":true}]
Income Taxes41.90M60.43M76.44M66.69M14.38M[{"date":"2019-12-31","value":54.82,"profit":true},{"date":"2020-12-31","value":79.06,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":87.24,"profit":true},{"date":"2023-12-31","value":18.81,"profit":true}]
Income After Taxes190.99M293.81M368.84M220.26M179.72M[{"date":"2019-12-31","value":51.78,"profit":true},{"date":"2020-12-31","value":79.66,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":59.72,"profit":true},{"date":"2023-12-31","value":48.73,"profit":true}]
Income From Continuous Operations190.99M293.81M368.84M220.26M49.88M[{"date":"2019-12-31","value":51.78,"profit":true},{"date":"2020-12-31","value":79.66,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":59.72,"profit":true},{"date":"2023-12-31","value":13.52,"profit":true}]
Income From Discontinued Operations-----[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Net Income157.29M224.40M265.85M213.92M179.72M[{"date":"2019-12-31","value":59.16,"profit":true},{"date":"2020-12-31","value":84.41,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":80.47,"profit":true},{"date":"2023-12-31","value":67.6,"profit":true}]
EPS (Diluted)1.432.022.782.222.18[{"date":"2019-12-31","value":51.44,"profit":true},{"date":"2020-12-31","value":72.66,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":79.86,"profit":true},{"date":"2023-12-31","value":78.42,"profit":true}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

INVA
Cash Ratio 1.16
Current Ratio 1.79
Quick Ratio 1.64

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

INVA
ROA (LTM) 9.37%
ROE (LTM) 9.97%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

INVA
Debt Ratio Lower is generally better. Negative is bad. 0.46
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.54

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

INVA
Trailing PE 23.01
Forward PE NM
P/S (TTM) 3.27
P/B 1.75
Price/FCF 24
EV/R 3.85
EV/Ebitda 11.02
PEG 0.24

FAQs

What is Innoviva Inc share price today?

Innoviva Inc (INVA) share price today is $18.32

Can Indians buy Innoviva Inc shares?

Yes, Indians can buy shares of Innoviva Inc (INVA) on Vested. To buy Innoviva Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in INVA stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Innoviva Inc be purchased?

Yes, you can purchase fractional shares of Innoviva Inc (INVA) via the Vested app. You can start investing in Innoviva Inc (INVA) with a minimum investment of $1.

How to invest in Innoviva Inc shares from India?

You can invest in shares of Innoviva Inc (INVA) via Vested in three simple steps:

  • Click on Sign Up or Invest in INVA stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Innoviva Inc shares
What is Innoviva Inc 52-week high and low stock price?

The 52-week high price of Innoviva Inc (INVA) is $21.28. The 52-week low price of Innoviva Inc (INVA) is $14.33.

What is Innoviva Inc price-to-earnings (P/E) ratio?

The price-to-earnings (P/E) ratio of Innoviva Inc (INVA) is 23.0125

What is Innoviva Inc price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Innoviva Inc (INVA) is 1.75

What is the Market Cap of Innoviva Inc?

The market capitalization of Innoviva Inc (INVA) is $1.15B

What is Innoviva Inc’s stock symbol?

The stock symbol (or ticker) of Innoviva Inc is INVA

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top